ライフサイエンスコーパス: vitrectomy

1 ts (anti-VEGF injections, laser therapy, and vitrectomy).

2 ntravitreal antibiotic administration and/or vitrectomy).

3 inage (drainage of sub-retinal fluid without vitrectomy).

4 made 3 mm away from the limbus along with a vitrectomy.

5 e need for retinal laser photocoagulation or vitrectomy.

6 , incidence of vitrectomy, and time to first vitrectomy.

7 hylaxis, prophylactic laser, or prophylactic vitrectomy.

8 t savings comparing PR to scleral buckle and vitrectomy.

9 f anti-VEGF medication, laser treatments, or vitrectomy.

10 went lensectomy, posterior capsulectomy, and vitrectomy.

11 her incidence of glaucoma after lens-sparing vitrectomy.

12 ears), 144 (0.02%) developed an MH requiring vitrectomy.

13 atient with keratoconus following pars plana vitrectomy.

14 idiopathic MH requiring surgical repair with vitrectomy.

15 al ganciclovir and laser photocoagulation or vitrectomy.

16 ith intravitreal antibiotics and 4 underwent vitrectomy.

17 rred in 0.35% of patients receiving anterior vitrectomy.

18 etinal fluid without the need for pars plana vitrectomy.

19 ith other ophthalmic surgeries, and anterior vitrectomy.

20 TRD during follow-up in 7 eyes, resulting in vitrectomy.

21 ctional abnormalities, normalized by limited vitrectomy.

22 ct surgery to 0.46 +/- 0.63 (P < .001) after vitrectomy.

23 T was compared with PVD determination during vitrectomy.

24 avitreal antibiotic injections or pars plana vitrectomy.

25 nd CSF measurements before and after limited vitrectomy.

26 ntioxidant levels in aqueous humor following vitrectomy.

27 nd P = .024, respectively) in patients after vitrectomy.

28 e pseudophakic, and they had undergone prior vitrectomies.

29 use of the trocars and cannulas as in adult vitrectomies.

30 itrectomies, and MERSI cases were diagnostic vitrectomies.

31 on injection (1), intraocular injection with vitrectomy (1), and eye drops (1).

32 dophthalmitis (2/19, 10.5%), post-pars plana vitrectomy (1/19, 5.3%), and post-scleral buckle exposur

33 Of these, 25 were dissatisfied and sought vitrectomy; 13 were satisfied with observation.

34 , and lowest in 7 patients with prophylactic vitrectomy (14.3%).

35 o assess the surgical outcomes of pars plana vitrectomy, 180 degrees inferior retinotomy and silicone

36 CSF in the patients who chose limited vitrectomy (2.51 +/- 0.46 %W; range 2.03-3.06 %W) was 41

37 raction (4/40 vs 1/15; P = .5), and anterior vitrectomy (2/40 vs 1/15; P = .4).

38 of 13 eyes (38%), including prior pars plana vitrectomy (3 eyes), history of retinal tear (1 eye), an

39 ents had an ophthalmic procedure, pars plana vitrectomy (4.8%) being the most common one.

40 toward vitrectomy with a distribution of 83% vitrectomy, 5% scleral buckling, and 12% pneumatic retin

41 penetrating keratoplasty was associated with vitrectomy (57 eyes, group 3).

42 rent Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic inject

43 Operations performed were vitrectomy (88%), combined vitrectomy and scleral buckle

44 Women had 24% decreased odds of undergoing vitrectomy (adjusted odds ratio [OR], 0.76; 95% confiden

45 Three cases among those undergoing vitrectomy after 3 months were complicated by retinal de

46 =20/200 vs. >/=20/40, aHR, 1.47); pars plana vitrectomy (aHR, 1.87); history of OHT in the other eye:

47 In the 3 patients who underwent vitrectomy, all 3 (100%) demonstrated redetachment resul

48 Pars plana vitrectomy alone with complete drainage of subretinal fl

49 idiopathic MH requiring surgical repair with vitrectomy among a large group of managed care plan bene

50 Combined 25-gauge posterior vitrectomy and 25-gauge trans-vitrector port needle aspi

51 eyes (33%) assigned to aflibercept received vitrectomy and 34 eyes (32%) assigned to vitrectomy rece

52 drome, 2 (12%) were aphakic after pars plana vitrectomy and 4 (24%) were aphakic after surgical inter

53 , Newark, DE) suture and combined pars plana vitrectomy and compare predicted refractive outcomes amo

54 toid macular changes treated with pars plana vitrectomy and epiretinal and internal limiting membrane

55 glaucoma, underwent surgery with pars plana vitrectomy and epiretinal and internal limiting membrane

56 itrated laser photocoagulation combined with vitrectomy and gas tamponade can safely create an effect

57 ser photocoagulation followed immediately by vitrectomy and gas tamponade.

58 pillary laser photocoagulation combined with vitrectomy and gas tamponade.

59 utcomes of retinal detachment (RD) repair by vitrectomy and perfluorocarbon liquid (PFCL) tamponade.

60 Pars plana vitrectomy and PPV-SB as the first procedure were perfor

61 ns performed were vitrectomy (88%), combined vitrectomy and scleral buckle (8%), and encirclement (3%

62 s (follow-up, FUP) after 23 gauge pars-plana vitrectomy and SF6 gas tamponade.

63 s (follow-up, FUP) after 23 gauge pars plana vitrectomy and SF6 gas tamponade.

64 The last patient had a pars plana vitrectomy and silicone oil instillation combined with p

65 Interventions included pars plana vitrectomy and silicone oil tamponade with or without sc

66 The safety profile was consistent with vitrectomy and the subretinal injection procedure, and n

67 TMC and BMC were therapeutic and diagnostic vitrectomies, and MERSI cases were diagnostic vitrectomi

68 rior hydrocephalus, 1 uveitis and pars plana vitrectomy, and 1 juvenile open-angle glaucoma) and 21 o

69 ewer than 10% of patients with BEE underwent vitrectomy, and 1.6% of BEE patients underwent enucleati

70 and pneumatic retinopexy; 3 (30%) underwent vitrectomy, and 5 (50%) with poor prognosis did not unde

71 corrected visual acuity (BCVA), incidence of vitrectomy, and time to first vitrectomy.

72 ain from baseline, nonsurgical FTMH closure, vitrectomy, and Visual Function Questionnaire 25 (VFQ-25

73 ncident DR requiring laser photocoagulation, vitrectomy, and/or antiangiogenic therapy confirmed by a

74 Systemic evaluation and visual outcome after vitrectomy are discussed.

75 ion of aflibercept followed by PRP and early vitrectomy are effective and safe modalities for treatme

76 s study evaluated a technique using 25-gauge vitrectomy as an adjunct to needle biopsy immediately be

77 osis, filtering surgery before keratoplasty, vitrectomy associated with keratoplasty, and filtering s

78 Two experienced surgeons performed vitrectomies at the Geneva University Eye Clinic.

79 injection of antibiotics or with pars plana vitrectomy at least twice were included.

80 ) and those who had partial PPVs or anterior vitrectomies (AVs) at the time of KPro implantation (n =

81 ages of 41 eyes with ERMs that had undergone vitrectomy by a single surgeon were analyzed to record t

82 mage to the trabecular meshwork in such post-vitrectomy cases may contribute to intraocular pressure

83 Five of 6 had surgeries such as vitrectomy, cataract extraction, or a procedure for glau

84 Scleral buckle and vitrectomy combined with belt buckle were performed in 4

85 A vitrectomy combined with ILMR and ABC is effective for c

86 tomy, posterior capsulorrhexis, and anterior vitrectomy combined with primary intraocular lens implan

87 ed poorer anatomic and visual outcomes after vitrectomy compared with FTMH without MHEP.

88 After vitrectomy, CSF improved by an average of 43.2%, normali

89 s treated with endoresection or endodrainage-vitrectomy developed less radiation retinopathy (30.5% a

90 ment for retinal photocoagulation therapy or vitrectomy, development of proliferative retinopathy, or

91 uge of instrumentation, and history of prior vitrectomy did not result in significant differences amo

92 der the curve, peripheral visual field loss, vitrectomy, DME development, and retinal neovascularizat

93 Both groups could receive aflibercept or vitrectomy during follow-up based on protocol criteria.

94 All patients underwent a vitrectomy during the course of their treatment, and all

95 Commercially available 23-gauge vitrectomy equipment, custom surgical forceps, and opera

96 lanoma underwent complete 25-gauge posterior vitrectomy followed by transvitrector port fine-needle a

97 High anatomical success rate of primary vitrectomy for complex RRD with either gas or SO tampona

98 ficant gains in visual acuity are seen after vitrectomy for diabetic TRD that can result in functiona

99 0) and US driving standards (>= 20/40) after vitrectomy for diabetic TRD.

100 nretinal photocoagulation (PRP) versus early vitrectomy for diabetic vitreous hemorrhage (VH).

101 ry and healing of outer retinal layers after vitrectomy for foveal detachment associated with optic d

102 To evaluate visual outcomes after vitrectomy for intraocular hemorrhages secondary to trau

103 20 patients (all male) underwent pars plana vitrectomy for intraocular hemorrhages secondary to trau

104 g a standard 20-gauge or 23-gauge pars plana vitrectomy for intraocular hemorrhages secondary to trau

105 ogical and functional changes of cones after vitrectomy for macula-off retinal detachment.

106 ologic and functional changes of cones after vitrectomy for macula-off retinal detachment.

107 Patients who underwent pars plana vitrectomy for macula-off rhegmatogenous retinal detachm

108 ation, and 3 eyes (50%) underwent subsequent vitrectomy for persistent endophthalmitis after a mean o

109 939 eyes of 834 patients undergoing primary vitrectomy for proliferative diabetic retinopathy at 16

110 assess the risks and benefits of pars plana vitrectomy for proliferative diabetic retinopathy, but c

111 Contemporary VA outcomes of 23-gauge vitrectomy for retained lens fragments are comparable wi

112 combined phacoemulsification and pars plana vitrectomy for retinal detachment and later silicone oil

113 Management changes on POD1 after vitrectomy for retinal detachment repair are relatively

114 t study of 506 eyes who underwent pars plana vitrectomy for rhegmatogenous retinal detachment (RRD) b

115 % retinal attachment was achieved by another vitrectomy for rhegmatogenous retinal detachment that oc

116 While performing vitrectomy for severe vitreous hemorrhage, a point of st

117 A total of 28 eyes in 20 patients undergoing vitrectomy for Terson syndrome secondary to traumatic br

118 ients fulfilling Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous

119 results from the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous

120 determined the cost-effectiveness of limited vitrectomy for this condition.

121 , consecutive patients who underwent primary vitrectomy for TRD from proliferative diabetic retinopat

122 Limited vitrectomy for vision-degrading myodesopsia is clinicall

123 Ten patients underwent vitrectomy for visually significant vitreous amyloidosis

124 In the IRIS Registry, eyes undergoing vitrectomy for vitreous opacities returned to the operat

125 t additional eye surgery within 1 year after vitrectomy for vitreous opacities were identified, as wa

126 try were analyzed for patients who underwent vitrectomy for vitreous opacities.

127 hese patients required subsequent pars plana vitrectomy for worsening clinical course.

128 Five patients required pars plana vitrectomy for worsening vitritis.

129 fluids were collected during 23G pars plana vitrectomy from 54 eyes of 54 patients with different RD

130 valent, 20/63) (95% CI, 58.6 to 67.3) in the vitrectomy group (adjusted difference, -5.0 [95% CI, -10

131 up included patients who were matched to the vitrectomy group 1:2 based on sex, diabetes mellitus (DM

132 p vs 62.3 (Snellen equivalent, 20/63) in the vitrectomy group at 4 weeks (adjusted difference, -11.2

133 The vitrectomy group included patients >=18 years of age who

134 nd P = .06 (comparator group vs endodrainage-vitrectomy group).

135 ening complications (P = 0.051) in the total vitrectomy group.

136 Diabetic vitrectomy has an appreciable complication rate, particu

137 Recently, 25-gauge vitrectomy has become more popular.

138 or missing posterior capsular membranes and vitrectomy histories present a high risk of anterior cha

139 re surgery based on VA compared to 28% after vitrectomy however this study did not examine visual fie

140 0.84; laser HR, 0.62; 95% CI, 0.47-0.81; and vitrectomy HR, 0.71; 95% CI, 0.59-0.85).

141 ed into 2 groups: Group 1 (20 eyes) received vitrectomy, ILM peeling within the arcade area, and air-

142 atment in 57 of 63 (90%) eyes and pars plana vitrectomy in 6 of 63 (10%) eyes.

143 icosteroids, antiviral medication, and early vitrectomy in many patients, visual outcomes typically w

144 to traumatic brain injury, and the timing of vitrectomy in relation to the inciting intracranial even

145 (95% CI 0.23 to 26.48, P = .44) with primary vitrectomy instead of a biopsy.

146 After core vitrectomy, internal limiting membrane (ILM) was peeled

147 phthalmic ultrasound, angioinhibitory drugs, vitrectomy, intraocular gases, and many others.

148 uid exchange, and Group 2 (20 eyes) received vitrectomy, inverted ILM inserted into the macular hole,

149 proach was lensectomy combined with anterior vitrectomy +/- IOL implantation (US-Cat: 98.65%; BS-Cat:

150 oval of vitreous as cleanly as possible when vitrectomy is performed in treating patients with prolif

151 adjuvant treatment option, the endodrainage-vitrectomy is recommended in patients who are ineligible

152 The role of prophylactic vitrectomy is still unclear, but deserves further invest

153 Early vitrectomy leads to faster vision gain with less inciden

154 tors related to, glaucoma after lens-sparing vitrectomy (LSV) surgery in advanced retinopathy of prem

155 Vitrectomy may be successful in closing the macular hole

156 Earlier vitrectomy may shorten recovery times for MG.

157 onade and 49 eyes (11.7%) undergoing further vitrectomy (median follow-up, 6.9 months); 17.9% of 127

158 onade and 78 eyes (15.0%) undergoing further vitrectomy (median follow-up, 7.1 months); 21.2% of 126

159 surgery and at 1, 3, 6, and 12 months after vitrectomy/membrane peel without chromodissection.

160 ility of the polymer endotamponade in rabbit vitrectomy models, and its surgical efficacy and biocomp

161 ar endothelial growth factor agents (n = 4), vitrectomy (n = 2), and cryotherapy (n = 1).

162 n = 3), scleral buckle (n = 2), pars plicata vitrectomy (n = 2), and no treatment (n = 2).

163 in 28.5% of patients, with a median time to vitrectomy of 63 days.

164 The surgical management using pars plana vitrectomy offers the most effective approach for VMT, b

165 Pars plana vitrectomy offers theoretical advantages but is generall

166 One eye underwent vitrectomy on presentation, and 3 eyes (50%) underwent s

167 itreous specimens from patients subjected to vitrectomy or buckling surgery for RRD.

168 ed to identify all enrollees who underwent 1 vitrectomy or more each year from 2001 through 2012.

169 brain injury, irrespective of the timing of vitrectomy or of preoperative visual acuity.

170 re all patients who required re-irradiation, vitrectomies, or tumor resections; and those whose treat

171 nagement strategy, surgical characteristics, vitrectomy outcomes, and significance of systemic evalua

172 eligible enrollees, 40 892 (0.4%) underwent vitrectomy over the 12-year period.

173 d with a higher rate of secondary pars plana vitrectomy (P = .009) and retinal detachment (P = .022).

174 .01), whether spontaneously (P < .01) or via vitrectomy (P = .04), but VA did not improve in holes th

175 with combined cataract surgery and anterior vitrectomy (P = .051), although only 0.08% of eyes had t

176 Precataract surgery and intraoperative (vitrectomy) parameters, postvitrectomy complications, an

177 Rates of vitrectomy per 1000 enrollees were computed each year fr

178 ted to show skill transfer from simulator to vitrectomies performed on cadavers.

179 Pars plana vitrectomy plus SB yielded a significantly higher SOAS t

180 anagement options for VMT include pars plana vitrectomy, pneumatic vitreolysis, enzymatic vitreolysis

181 Following prior pars plana vitrectomy, pO(2) levels were significantly higher than

182 n different indications for trans pars plana vitrectomies (PPV's) and the intraocular pressure (IOP),

183 disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39;

184 nal detachment (RRD) repair using pars plana vitrectomy (PPV) alone versus combined scleral buckling

185 All cases were treated with pars plana vitrectomy (PPV) and a double silicone oil endotamponade

186 Nondiabetic eyes undergoing pars plana vitrectomy (PPV) and silicone oil tamponade with or with

187 l patients with RRD who underwent pars plana vitrectomy (PPV) between January 2013 and December 2017

188 Venous air embolism (VAE) during pars plana vitrectomy (PPV) can occur owing to improper positioning

189 raphy data (iOCT) in all steps of pars plana vitrectomy (PPV) for non-RRD in MGS, in order to follow

190 al photocoagulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and study eye changes on the D

191 n in diabetic subjects undergoing pars plana vitrectomy (PPV) for severe manifestations of active pro

192 pneumatic retinopexy (PnR) versus pars plana vitrectomy (PPV) for the management of primary RRD.

193 Previous pars plana vitrectomy (PPV) had been performed in 3 eyes (1 for RD,

194 olarity after micro-incision 25G+ pars plana vitrectomy (PPV) in a prospective study.

195 Pars plana vitrectomy (PPV) in eyes with history of retinoblastoma

196 longer-term outcomes of 27-gauge pars plana vitrectomy (PPV) in eyes with posterior segment disease.

197 ss of prophylactic laser or early pars plana vitrectomy (PPV) in preventing retinal detachment (RD) r

198 Pars plana vitrectomy (PPV) is preferred surgical procedure for the

199 code for intravitreal injections, pars plana vitrectomy (PPV) or laser treatment in their record foll

200 nal detachment (RRD) treated with pars plana vitrectomy (PPV) or PPV with scleral buckle (PPV-SB).

201 yes (n = 12) underwent an initial pars plana vitrectomy (PPV) with intravitreal antibiotics, none of

202 ical and functional results after pars plana vitrectomy (PPV) with sulfur hexafluoride (SF6) gas tamp

203 ive percent of patients underwent pars plana vitrectomy (PPV), 50% underwent encircling scleral buckl

204 re compared, including repeat PR, pars plana vitrectomy (PPV), and combined scleral buckle (SB) plus

205 prior to the study, a history of pars plana vitrectomy (PPV), and less than 1 year of follow-up.

206 -term silicone oil tamponade after par plana vitrectomy (PPV), and to compare the outcomes of differe

207 Surgical treatment involves pars plana vitrectomy (PPV), often combined with adjunctive procedu

208 treated with scleral buckle (SB), pars plana vitrectomy (PPV), or SB combined with PPV (PPV/SB).

209 ntial, bilateral RRD treated with pars plana vitrectomy (PPV), scleral buckle (SB), or PPV plus SB ov

210 All patients undergoing pars plana vitrectomy (PPV), scleral buckling (SB), and combined PP

211 Twenty-six eyes underwent pars plana vitrectomy (PPV).

212 ntravitreal antifungal injection, pars plana vitrectomy (PPV).

213 ataract extraction (CE) following pars plana vitrectomy (PPV).

214 rventions for RRD repair included pars plana vitrectomy (PPV; 15 patients), combined scleral buckle a

215 CI, 1.1-4.5) and combined SB plus pars plana vitrectomy (PPV; 68%; OR, 2.3; 95% CI, 1.1-5.1) compared

216 ntion (pneumatic retinopexy [PR], pars plana vitrectomy [PPV], laser barricade, or scleral buckle [SB

217 To determine the impact of total pars plana vitrectomies (PPVs) with peripheral shaving of the vitre

218 During this same period, the vitrectomy rate among persons with diabetes mellitus dec

219 wever, among persons with diabetes mellitus, vitrectomy rates declined substantially over this period

220 Overall vitrectomy rates increased 31% from 2001 to 2012 (from 1

221 Overall, we observed an increase in the vitrectomy rates per 1000 enrollees in this large manage

222 ved vitrectomy and 34 eyes (32%) assigned to vitrectomy received subsequent aflibercept.

223 All eyes underwent pars plana vitrectomy, removal of any epiretinal membranes, and gas

224 nd 60.8% when compared to scleral buckle and vitrectomy, respectively.

225 ead to different surgical procedures such as vitrectomy resulting in unfavorable outcomes.

226 The percentage of eyes that underwent vitrectomy, scleral buckle surgery, and pneumatic retino

227 Currently, surgical techniques, including vitrectomy, scleral buckle, and pneumatic retinopexy, ar

228 Previous scleral buckling or pars plana vitrectomy seem to have no impact on the success of the

229 Participants seeking vitrectomy showed 24% greater vitreous echodensity (P =

230 In the vitrectomy subgroup, mean BCVA increased (P = .01) and C

231 ed pO(2) and antioxidant depletion following vitrectomy suggests an alteration of the intraocular oxi

232 e dexamethasone (Ozurdex) at the time of (1) vitrectomy surgery and (2) silicone oil removal.

233 Phakic status and previous vitrectomy surgery do not appear to influence these valu

234 eight hundred thirty-six eyes that underwent vitrectomy surgery linked to one of the ICD-9-CM or ICD-

235 ary anatomic success rate in eyes undergoing vitrectomy surgery with silicone oil for PVR.

236 A total of 140 patients requiring vitrectomy surgery with silicone oil for retinal detachm

237 Laser photocoagulation and vitrectomy surgery, the standard interventions for PSR,

238 sed factors affecting the odds of undergoing vitrectomy surgery.

239 urrent Procedural Terminology (CPT) code for vitrectomy surgery.

240 e associated with developing an MH requiring vitrectomy; the effect varies across ages differently fo

241 Only poorer precataract surgery VA, delaying vitrectomy to later than 2 weeks, and final aphakic stat

242 ntrol subjects (n = 3) undergoing pars plana vitrectomy to remove an epiretinal membrane (ERM), and t

243 1260 procedures in 2014 (P < 0.01), whereas vitrectomy use for retinal detachment increased from 13

244 All patients underwent vitrectomy using a semicircular single-layered ILM inver

245 ctive chart review of patients who underwent vitrectomy using PFCL tamponade for RD repair from cause

246 Pars plana vitrectomy usually was performed in patients with persis

247 ntal patient value gain conferred by limited vitrectomy was 2.38 quality-adjusted life-years (QALYs),

248 The average age of those undergoing vitrectomy was 57+/-13 years.

249 With regard to management, pars plana vitrectomy was associated with increased probability of

250 Vitrectomy was done for three eyes (17.6%) due to recurr

251 g 2 eyes had vitreous hemorrhage; endoscopic vitrectomy was done in them to detect an inoperable reti

252 and group IotaIota (17 eyes) for whom early vitrectomy was done.

253 Pars plana vitrectomy was frequently performed regardless of the pr

254 Vitrectomy was more likely to be successful in eyes with

255 Pars plana vitrectomy was most common (49%), followed by laser barr

256 Vitrectomy was performed as early as corneal clarity per

257 Limited vitrectomy was performed in 11 of 40 cases (27.5%), norm

258 Vitrectomy was performed in 2 patients, and in 1 of thes

259 Vitrectomy was performed in 28.5% of patients, with a me

260 Vitrectomy was performed when vitreous inflammation was

261 If vitrectomy was performed within 30 days, recovery of ana

262 th proliferative diabetic retinopathy (PDR), vitrectomy was resorted for non clearing vitreous hemorr

263 Subretinal injection with pars plana vitrectomy was well tolerated in this cohort.

264 eous biopsy, followed by 25-gauge pars plana vitrectomy, was performed in the same sitting in all cas

265 The odds of undergoing a vitrectomy were 17% greater for black persons (adjusted

266 nterface abnormalities or that had undergone vitrectomy were excluded.

267 or EK performed in conjunction with anterior vitrectomy were significantly higher than after either P

268 ith Nd:YAG, 25 were dissatisfied and seeking vitrectomy, whereas 13 were satisfied with observation.

269 e was unsuccessful, necessitating pars plana vitrectomy, while in a case with proliferative diabetic

270 eal injections of antibiotics and pars plana vitrectomies with intravitreal antibiotics.

271 lar holes that underwent 23-gauge pars plana vitrectomy with 2 cc pure SF6 gas tamponade.

272 Either pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN

273 nal detachment repair shifted further toward vitrectomy with a distribution of 83% vitrectomy, 5% scl

274 519 eyes (among 463 patients) that underwent vitrectomy with delamination, the intraoperative complic

275 > 400 mum) treated with 25-gauge pars-plana vitrectomy with either complete ILM peeling (n = 23, Gro

276 In glaucomatous eyes, pars plana vitrectomy with epiretinal and internal limiting membran

277 Pars plana vitrectomy with ERM removal and ILM peeling was performe

278 es METHODS STUDY POPULATION: Five eyes after vitrectomy with gas for macula-off retinal detachment (r

279 StudyPopulation: Five eyes after vitrectomy with gas for macula-off retinal detachment (r

280 al detachment, before and for 10 years after vitrectomy with gas.

281 ary (CSB) recover visual acuity faster after vitrectomy with ILM peeling for ERM.

282 Patients underwent pars plana vitrectomy with internal limiting membrane peeling and s

283 Pars plana vitrectomy with internal limiting membrane peeling follo

284 antibiotic injection (n = 5) and pars plana vitrectomy with intravitreal antibiotic injection (n = 5

285 rane formation, for which she had pars plana vitrectomy with membrane peeling.

286 Pars plana vitrectomy with or without delamination/segmentation.

287 repair with either a scleral buckle (SB) or vitrectomy with or without scleral buckle (PPV+/-SB) bet

288 cipant) to aflibercept (100 participants) or vitrectomy with panretinal photocoagulation (105 partici

289 treatment with intravitreous aflibercept vs vitrectomy with panretinal photocoagulation.

290 ically important benefit in favor of initial vitrectomy with panretinal photocoagulation.

291 ents with center-involved DME that underwent vitrectomy with peeling of the internal limiting membran

292 PFO were compared to 29 eyes that underwent vitrectomy with perfluorodecalin.

293 A total of 48 eyes that underwent vitrectomy with PFO were compared to 29 eyes that underw

294 These data also suggest that vitrectomy with removal of DEX may not be necessary in a

295 For eyes undergoing pars plana vitrectomy with scleral-sutured IOL implantation, assump

296 e comparative case series of eyes undergoing vitrectomy with silicone oil tamponade for retinal detac

297 All patients underwent a pars plana vitrectomy with subretinal implantation of human amnioti

298 outcomes between the individuals undergoing vitrectomy within 3 months of the inciting event, 0.08+/

299 420 eyes (among 408 patients) that underwent vitrectomy without delamination, the intraoperative comp

300 avitreal, and topical), and 2 eyes underwent vitrectomy without improvement in vision.